We investigated the clinical efficacy and remission rates of tezepelumab at our hospital. In the treatment-naïve group (patients with no history of receiving biologics), significant improvements in forced expiratory volume, asthma control test, and asthma control questionnaire scores, as well as decreases in blood eosinophil counts and fractional exhaled nitric oxide (FeNO) levels, were observed. The 3-way remission (stability of symptoms, no exacerbation, no systemic steroids) rate at 12 months was high (72.7 %). Particularly, its effectiveness was higher in patients with higher blood eosinophil counts and FeNO levels. This suggests that tezepelumab may be more effective in patients with stronger type 2 inflammation.

View full abstract